Home » Stocks » Precision BioSciences

Precision BioSciences, Inc. (DTIL)

Stock Price: $8.08 USD -0.15 (-1.82%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 419.04M
Revenue (ttm) 23.77M
Net Income (ttm) -87.93M
Shares Out 51.86M
EPS (ttm) -1.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 10, 2020
Last Price $8.08
Previous Close $8.23
Change ($) -0.15
Change (%) -1.82%
Day's Open 8.16
Day's Range 7.98 - 8.41
Day's Volume 333,028
52-Week Range 4.60 - 23.67

More Stats

Market Cap 419.04M
Enterprise Value 276.06M
Earnings Date (est) Aug 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 51.86M
Float 38.99M
EPS (basic) -1.68
EPS (diluted) -1.73
FCF / Share -1.90
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.28M
Short Ratio 2.26
Short % of Float 3.79%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 17.63
PB Ratio 3.73
Revenue 23.77M
Operating Income -95.21M
Net Income -87.93M
Free Cash Flow -97.71M
Net Cash 142.98M
Net Cash / Share 2.76
Gross Margin 93.54%
Operating Margin -400.46%
Profit Margin -369.90%
FCF Margin -410.97%
ROA -31.24%
ROE -139.72%
ROIC -271.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 7
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(145.79% upside)
Current: 8.08
Target: 19.86
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth104.34%67.84%-
Gross Profit22.2410.886.48
Operating Income-87.20-47.91-21.97
Net Income-92.88-46.04-21.10
Shares Outstanding41.9915.7815.91
Earnings Per Share-2.21-2.92-1.33
Operating Cash Flow-71.02-51.72-24.17
Capital Expenditures-24.67-15.66-5.52
Free Cash Flow-95.68-67.39-29.68
Cash & Equivalents18110362.80
Net Cash / Debt18110362.80
Book Value13839.96-26.37
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Precision BioSciences, Inc.
Country United States
Employees 225
CEO Matthew R. Kane

Stock Information

Ticker Symbol DTIL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: DTIL


Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.